| Respiratory And Rehabilitation Center Of Ri | |
| 10 Woodland Drive, Coventry, Rhode Island 02816 | |
| (401) 826-2000 | |
| Name | Respiratory And Rehabilitation Center Of Ri |
|---|---|
| Location | 10 Woodland Drive, Coventry, Rhode Island |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 210 |
| Occupancy Rate | 64.81% |
| Medicare ID (CCN) | 415078 |
| Legal Business Name | 10 Woodland Drive Operations Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1114709581 |
| Organization Name | COVENTRY OPERATIONS RI LLC |
| Address | 10 Woodland Dr, Coventry, RI 02816 |
| Phone Number | 908-414-8026 |
News Archive
The Walter Reed Army Institute of Research began vaccinations today in a Phase 1 clinical trial to evaluate the safety and immune response of a vaccine candidate to prevent Middle East Respiratory Syndrome (MERS).
A leading scientific journal in Pakistan, The Journal of Management & Social Science, recently published a paper titled "A New Role for the Military: Preventing Enemies from Arising-Reviving an Ancient Approach to Peace," indicating that the military application of the Transcendental Meditation technique has merit. The paper discusses how militaries worldwide could use the Transcendental Meditation- and TM-Sidhi- program, founded by Maharishi Mahesh Yogi, as a non-religious and scientifically verified way to prevent war and terrorism. When used in a military context, these meditation practices are known as Invincible Defense Technology (IDT).
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
NanoViricides, Inc. announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development of the US FDA for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.
In a post in USAID's "IMPACTblog," CARE President and CEO Helene Gayle describes a new multi-partner initiative, called "Women and Girls Lead Global," which aims to spread "the stories of ... resilient women and girls" through documentary films that will air in nine countries over three years.
› Verified 4 days ago
| NPI Number | 1275506230 |
| Organization Name | HAVEN HEALTH CENTER OF COVENTRY, LLC |
| Address | 10 Woodland Dr, Coventry, RI 02816 |
| Phone Number | 401-826-2000 |
News Archive
The Walter Reed Army Institute of Research began vaccinations today in a Phase 1 clinical trial to evaluate the safety and immune response of a vaccine candidate to prevent Middle East Respiratory Syndrome (MERS).
A leading scientific journal in Pakistan, The Journal of Management & Social Science, recently published a paper titled "A New Role for the Military: Preventing Enemies from Arising-Reviving an Ancient Approach to Peace," indicating that the military application of the Transcendental Meditation technique has merit. The paper discusses how militaries worldwide could use the Transcendental Meditation- and TM-Sidhi- program, founded by Maharishi Mahesh Yogi, as a non-religious and scientifically verified way to prevent war and terrorism. When used in a military context, these meditation practices are known as Invincible Defense Technology (IDT).
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
NanoViricides, Inc. announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development of the US FDA for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.
In a post in USAID's "IMPACTblog," CARE President and CEO Helene Gayle describes a new multi-partner initiative, called "Women and Girls Lead Global," which aims to spread "the stories of ... resilient women and girls" through documentary films that will air in nine countries over three years.
› Verified 4 days ago
| NPI Number | 1558658963 |
| Organization Name | COVENTRY SKILLED NURSING AND REHAB |
| Address | 10 Woodland Drive, Coventry, RI 02816 |
| Phone Number | 401-826-2000 |
News Archive
The Walter Reed Army Institute of Research began vaccinations today in a Phase 1 clinical trial to evaluate the safety and immune response of a vaccine candidate to prevent Middle East Respiratory Syndrome (MERS).
A leading scientific journal in Pakistan, The Journal of Management & Social Science, recently published a paper titled "A New Role for the Military: Preventing Enemies from Arising-Reviving an Ancient Approach to Peace," indicating that the military application of the Transcendental Meditation technique has merit. The paper discusses how militaries worldwide could use the Transcendental Meditation- and TM-Sidhi- program, founded by Maharishi Mahesh Yogi, as a non-religious and scientifically verified way to prevent war and terrorism. When used in a military context, these meditation practices are known as Invincible Defense Technology (IDT).
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
NanoViricides, Inc. announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development of the US FDA for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.
In a post in USAID's "IMPACTblog," CARE President and CEO Helene Gayle describes a new multi-partner initiative, called "Women and Girls Lead Global," which aims to spread "the stories of ... resilient women and girls" through documentary films that will air in nine countries over three years.
› Verified 4 days ago
| NPI Number | 1700173788 |
| Address | 10 Woodland Dr, Coventry, RI 02816 |
| Phone Number | 401-826-2000 |
News Archive
The Walter Reed Army Institute of Research began vaccinations today in a Phase 1 clinical trial to evaluate the safety and immune response of a vaccine candidate to prevent Middle East Respiratory Syndrome (MERS).
A leading scientific journal in Pakistan, The Journal of Management & Social Science, recently published a paper titled "A New Role for the Military: Preventing Enemies from Arising-Reviving an Ancient Approach to Peace," indicating that the military application of the Transcendental Meditation technique has merit. The paper discusses how militaries worldwide could use the Transcendental Meditation- and TM-Sidhi- program, founded by Maharishi Mahesh Yogi, as a non-religious and scientifically verified way to prevent war and terrorism. When used in a military context, these meditation practices are known as Invincible Defense Technology (IDT).
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
NanoViricides, Inc. announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development of the US FDA for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.
In a post in USAID's "IMPACTblog," CARE President and CEO Helene Gayle describes a new multi-partner initiative, called "Women and Girls Lead Global," which aims to spread "the stories of ... resilient women and girls" through documentary films that will air in nine countries over three years.
› Verified 4 days ago
| NPI Number | 1861770745 |
| Organization Name | GENESIS |
| Address | 10 Woodland Dr, Coventry, RI 02816 |
| Phone Number | 401-826-2000 |
News Archive
The Walter Reed Army Institute of Research began vaccinations today in a Phase 1 clinical trial to evaluate the safety and immune response of a vaccine candidate to prevent Middle East Respiratory Syndrome (MERS).
A leading scientific journal in Pakistan, The Journal of Management & Social Science, recently published a paper titled "A New Role for the Military: Preventing Enemies from Arising-Reviving an Ancient Approach to Peace," indicating that the military application of the Transcendental Meditation technique has merit. The paper discusses how militaries worldwide could use the Transcendental Meditation- and TM-Sidhi- program, founded by Maharishi Mahesh Yogi, as a non-religious and scientifically verified way to prevent war and terrorism. When used in a military context, these meditation practices are known as Invincible Defense Technology (IDT).
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
NanoViricides, Inc. announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development of the US FDA for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.
In a post in USAID's "IMPACTblog," CARE President and CEO Helene Gayle describes a new multi-partner initiative, called "Women and Girls Lead Global," which aims to spread "the stories of ... resilient women and girls" through documentary films that will air in nine countries over three years.
› Verified 4 days ago
| NPI Number | 1912158528 |
| Organization Name | 10 WOODLAND DRIVE OPERATIONS LLC |
| Doing Business As | RESPIRATORY AND REHABILITATION CENTER OF RHODE ISLAND |
| Address | 10 Woodland Dr, Coventry, RI 02816 |
| Phone Number | 401-826-2000 |
News Archive
The Walter Reed Army Institute of Research began vaccinations today in a Phase 1 clinical trial to evaluate the safety and immune response of a vaccine candidate to prevent Middle East Respiratory Syndrome (MERS).
A leading scientific journal in Pakistan, The Journal of Management & Social Science, recently published a paper titled "A New Role for the Military: Preventing Enemies from Arising-Reviving an Ancient Approach to Peace," indicating that the military application of the Transcendental Meditation technique has merit. The paper discusses how militaries worldwide could use the Transcendental Meditation- and TM-Sidhi- program, founded by Maharishi Mahesh Yogi, as a non-religious and scientifically verified way to prevent war and terrorism. When used in a military context, these meditation practices are known as Invincible Defense Technology (IDT).
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
NanoViricides, Inc. announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development of the US FDA for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.
In a post in USAID's "IMPACTblog," CARE President and CEO Helene Gayle describes a new multi-partner initiative, called "Women and Girls Lead Global," which aims to spread "the stories of ... resilient women and girls" through documentary films that will air in nine countries over three years.
› Verified 4 days ago
| NPI Number | 1922260272 |
| Organization Name | TC HEALTHCARE I, LLC |
| Doing Business As | COVENTRY HEALTH CARE FACILITY |
| Address | 10 Woodland Dr, Coventry, RI 02816 |
| Phone Number | 401-826-2000 |
News Archive
The Walter Reed Army Institute of Research began vaccinations today in a Phase 1 clinical trial to evaluate the safety and immune response of a vaccine candidate to prevent Middle East Respiratory Syndrome (MERS).
A leading scientific journal in Pakistan, The Journal of Management & Social Science, recently published a paper titled "A New Role for the Military: Preventing Enemies from Arising-Reviving an Ancient Approach to Peace," indicating that the military application of the Transcendental Meditation technique has merit. The paper discusses how militaries worldwide could use the Transcendental Meditation- and TM-Sidhi- program, founded by Maharishi Mahesh Yogi, as a non-religious and scientifically verified way to prevent war and terrorism. When used in a military context, these meditation practices are known as Invincible Defense Technology (IDT).
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
NanoViricides, Inc. announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development of the US FDA for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.
In a post in USAID's "IMPACTblog," CARE President and CEO Helene Gayle describes a new multi-partner initiative, called "Women and Girls Lead Global," which aims to spread "the stories of ... resilient women and girls" through documentary films that will air in nine countries over three years.
› Verified 4 days ago
| NPI Number | 1942596580 |
| Address | 10 Woodland Dr, Coventry, RI 02816 |
| Phone Number | 401-826-2000 |
News Archive
The Walter Reed Army Institute of Research began vaccinations today in a Phase 1 clinical trial to evaluate the safety and immune response of a vaccine candidate to prevent Middle East Respiratory Syndrome (MERS).
A leading scientific journal in Pakistan, The Journal of Management & Social Science, recently published a paper titled "A New Role for the Military: Preventing Enemies from Arising-Reviving an Ancient Approach to Peace," indicating that the military application of the Transcendental Meditation technique has merit. The paper discusses how militaries worldwide could use the Transcendental Meditation- and TM-Sidhi- program, founded by Maharishi Mahesh Yogi, as a non-religious and scientifically verified way to prevent war and terrorism. When used in a military context, these meditation practices are known as Invincible Defense Technology (IDT).
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
NanoViricides, Inc. announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development of the US FDA for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.
In a post in USAID's "IMPACTblog," CARE President and CEO Helene Gayle describes a new multi-partner initiative, called "Women and Girls Lead Global," which aims to spread "the stories of ... resilient women and girls" through documentary films that will air in nine countries over three years.
› Verified 4 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
The Walter Reed Army Institute of Research began vaccinations today in a Phase 1 clinical trial to evaluate the safety and immune response of a vaccine candidate to prevent Middle East Respiratory Syndrome (MERS).
A leading scientific journal in Pakistan, The Journal of Management & Social Science, recently published a paper titled "A New Role for the Military: Preventing Enemies from Arising-Reviving an Ancient Approach to Peace," indicating that the military application of the Transcendental Meditation technique has merit. The paper discusses how militaries worldwide could use the Transcendental Meditation- and TM-Sidhi- program, founded by Maharishi Mahesh Yogi, as a non-religious and scientifically verified way to prevent war and terrorism. When used in a military context, these meditation practices are known as Invincible Defense Technology (IDT).
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
NanoViricides, Inc. announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development of the US FDA for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.
In a post in USAID's "IMPACTblog," CARE President and CEO Helene Gayle describes a new multi-partner initiative, called "Women and Girls Lead Global," which aims to spread "the stories of ... resilient women and girls" through documentary films that will air in nine countries over three years.
› Verified 4 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 20 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 7.32 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 23.73 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 2.03 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.2 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0.7 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 5.84 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 89.65 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 19.43 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 71.03 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0.94 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 49.49 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 21.75 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 6.05 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 96.09 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 57.8 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 86.01 | 82.93 |
News Archive
The Walter Reed Army Institute of Research began vaccinations today in a Phase 1 clinical trial to evaluate the safety and immune response of a vaccine candidate to prevent Middle East Respiratory Syndrome (MERS).
A leading scientific journal in Pakistan, The Journal of Management & Social Science, recently published a paper titled "A New Role for the Military: Preventing Enemies from Arising-Reviving an Ancient Approach to Peace," indicating that the military application of the Transcendental Meditation technique has merit. The paper discusses how militaries worldwide could use the Transcendental Meditation- and TM-Sidhi- program, founded by Maharishi Mahesh Yogi, as a non-religious and scientifically verified way to prevent war and terrorism. When used in a military context, these meditation practices are known as Invincible Defense Technology (IDT).
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
NanoViricides, Inc. announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development of the US FDA for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.
In a post in USAID's "IMPACTblog," CARE President and CEO Helene Gayle describes a new multi-partner initiative, called "Women and Girls Lead Global," which aims to spread "the stories of ... resilient women and girls" through documentary films that will air in nine countries over three years.
› Verified 4 days ago
Respiratory And Rehabilitation Center Of Ri Location: 10 Woodland Drive, Coventry, Rhode Island 02816 Phone: (401) 826-2000 | |
Riverview Healthcare Community Location: 546 Main Street, Coventry, Rhode Island 02816 Phone: (401) 821-6837 | |
Alpine Nursing Home Inc Location: 557 Weaver Hill Road, Coventry, Rhode Island 02816 Phone: (401) 397-5001 |